These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 16838823)

  • 1. Pharmacotherapies in the management of obsessive-compulsive disorder.
    Blier P; Habib R; Flament MF
    Can J Psychiatry; 2006 Jun; 51(7):417-30. PubMed ID: 16838823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapy for obsessive-compulsive disorder.
    Dougherty DD; Rauch SL; Jenike MA
    J Clin Psychol; 2004 Nov; 60(11):1195-202. PubMed ID: 15389617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological management of obsessive-compulsive disorder: a review for clinicians.
    McDonough M; Kennedy N
    Harv Rev Psychiatry; 2002; 10(3):127-37. PubMed ID: 12023928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
    Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
    Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
    Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
    Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment.
    Poyurovsky M; Weizman A; Weizman R
    CNS Drugs; 2004; 18(14):989-1010. PubMed ID: 15584769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment-resistant anxiety disorders: A literature review of drug therapy strategies].
    Ammar G; Naja WJ; Pelissolo A
    Encephale; 2015 Jun; 41(3):260-5. PubMed ID: 25439852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Mohr N; Vythilingum B; Emsley RA; Stein DJ
    Int Clin Psychopharmacol; 2002 Jan; 17(1):37-40. PubMed ID: 11800505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder.
    El Mansari M; Blier P
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 May; 30(3):362-73. PubMed ID: 16427729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
    Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
    JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Psychopharmacology of Obsessive-Compulsive Disorder: A Preclinical Roadmap.
    Szechtman H; Harvey BH; Woody EZ; Hoffman KL
    Pharmacol Rev; 2020 Jan; 72(1):80-151. PubMed ID: 31826934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological treatment strategies in obsessive compulsive disorder: A cross-sectional view in nine international OCD centers.
    Van Ameringen M; Simpson W; Patterson B; Dell'Osso B; Fineberg N; Hollander E; Hranov L; Hranov G; Lochner C; Karamustafalioglu O; Marazziti D; Menchon JM; Nicolini H; Pallanti S; Stein DJ; Zohar J
    J Psychopharmacol; 2014 Jun; 28(6):596-602. PubMed ID: 24429223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series.
    Van Ameringen M; Mancini C; Patterson B; Bennett M
    Depress Anxiety; 2006; 23(1):1-5. PubMed ID: 16178009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diversity of obsessive-compulsive disorder and pharmacotherapy associated with obsessive-compulsive spectrum disorders].
    Nakamae T
    Seishin Shinkeigaku Zasshi; 2011; 113(10):1016-25. PubMed ID: 22187889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The future of pharmacotherapy for obsessive-compulsive disorder may lie in a better understanding of its heterogeneity.
    Brakoulias V
    Expert Opin Pharmacother; 2014 Jul; 15(10):1321-3. PubMed ID: 24866422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapeutic Strategies and New Targets in OCD.
    Pittenger C
    Curr Top Behav Neurosci; 2021; 49():331-384. PubMed ID: 33751503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropsychological performance in medicated vs. unmedicated patients with obsessive-compulsive disorder.
    Mataix-Cols D; Alonso P; Pifarré J; Menchón JM; Vallejo J
    Psychiatry Res; 2002 Apr; 109(3):255-64. PubMed ID: 11959362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacological treatments for obsessive-compulsive disorder and the serotonin-dopamine hypothesis].
    Okamoto Y
    Seishin Shinkeigaku Zasshi; 2011; 113(1):36-44. PubMed ID: 21404630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.
    Denys D; de Geus F; van Megen HJ; Westenberg HG
    J Clin Psychiatry; 2004 Aug; 65(8):1040-8. PubMed ID: 15323587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.
    Saxena S; Wang D; Bystritsky A; Baxter LR
    J Clin Psychiatry; 1996 Jul; 57(7):303-6. PubMed ID: 8666572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.